A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- Registration Number
- NCT02819635
- Lead Sponsor
- AbbVie
- Brief Summary
This study was comprised of three substudies. The objective of Substudy 1 was to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission to identify the induction dose of upadacitinib for further evaluation in Substudy 2. The objective of Substudy 2 was to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission in participants. The objective of Substudy 3 was to evaluate the efficacy and safety of upadacitinib compared to placebo in achieving clinical remission in participants who had a response following induction with upadacitinib.
- Detailed Description
Substudy 1 was a Phase 2b dose-ranging study designed to evaluate the efficacy and safety of different oral doses of upadacitinib compared to placebo as 8-week induction therapy in participants with moderately to severely active UC. Approximately 250 participants were planned to be randomized 1:1:1:1:1 to the placebo group and 4 upadacitinib doses (7.5, 15, 30, and 45 mg). Randomization was stratified by previous biologic therapy use (yes/no), Baseline corticosteroid use (yes/no), and Baseline Adapted Mayo score (≤ 7 or \> 7). The study duration included a Screening Period of up to 5 weeks and an 8-week double-blind (DB) Induction Period. After all randomized participants completed the 8-week induction, a dose-selection analysis of efficacy and safety (selected laboratory parameters) of upadacitinib versus placebo was performed. Based on this dose-selection analysis, one induction dose (upadacitinib 45 mg) was identified for further evaluation in two Phase 3 induction studies, M14-234 Substudy 2 and M14-675 (NCT03653026). During the analysis period, 132 additional participants were randomized into Groups 3 and 4 of Substudy 1 (upadacitinib 30 mg and 45 mg dose groups; approximately 66 participants per dose group). The objectives of enrolling these additional participants were to avoid interrupting the study activities during the analysis period and to support a sufficient number of participants with clinical response to be re-randomized into the maintenance portion in Substudy 3. Substudy 1 main participants are defined as those first 250 randomized 250, and additional participants are defined as those who were randomized after the main participants.
Substudy 2 was a two-part Phase 3 dose-confirming study designed to evaluate the efficacy and safety of oral administration of upadacitinib 45 mg compared to placebo as induction therapy for up to 16 weeks in participants with moderately to severely active UC. Substudy 2 included a Screening Period of up to 5 weeks, Part 1, and Part 2. Part 1 was a randomized, DB, placebo-controlled 8-week induction period. Part 2 was an open-label, 8-week extended treatment period for clinical non-responders from Part 1 of Substudy 2. Part 1 was planned to enroll 462 subjects; actual enrollment was 474 subjects. Eligible participants were randomized in a 2:1 ratio to one of the two treatment groups (DB upadacitinib 45 mg or matching placebo) for 8 weeks. The randomization was stratified by bio-IR status (Biologic inadequate responders \[bio-IR\] vs Non-biologic-inadequate responders \[non-bio-IR\], corticosteroid use (yes or no), and Adapted Mayo score (≤ 7 or \> 7) at Baseline. Within bio-IR, the randomization was further stratified by number of prior biologic treatments (≤ 1 or \> 1). Within non-bio-IR, the randomization was further stratified by previous biologic use (yes or no). Part 2 was an open label, 8-week Extended Treatment Period for those who did not achieve clinical response per Adapted Mayo score at Week 8 in Part 1. All participants received upadacitinib 45 mg.
Substudy 3 was a Phase 3 maintenance study designed to evaluate the efficacy and safety of upadacitinib 15 and 30 mg once daily (QD) compared to placebo in achieving clinical remission per Adapted Mayo score in participants with moderately to severely active UC who achieved clinical response per Adapted Mayo score following induction therapy from Substudy 1, Substudy 2, or Study M14-675. A total of 1,046 subjects who achieved clinical response per Adapted Mayo score after completion of induction treatment or Extended Treatment Period in Study M14-234 Substudy 1, Substudy 2, or Study M14-675 entered Substudy 3, and 1,044 were treated with a blinded treatment assignment for up to 52 weeks. Substudy 3 included 4 cohorts. Cohort 1: 847 participants who achieved clinical response in Substudy 1, Substudy 2, or Study M14-675 at either Week 8 or Week 16, and received upadacitinib 15, 30, or 45 mg QD. The treatment groups in Cohort 1 were Group 1: upadacitinib 15 mg QD; Group 2: upadacitinib 30 mg QD; and Group 3: placebo QD. Those who achieved clinical response and received upadacitinib 15 mg QD in Substudy 1 were re-randomized 1:1 to only receive upadacitinib 15 mg QD or placebo QD (treatment Group 1 or 3). Cohort 2: 104 participants who received double-blind placebo QD treatment for 8 weeks during Substudy 1, Substudy 2 Part 1, or Study M14-675 Part 1 and achieved clinical response at Week 8 continued to receive blinded placebo QD in Substudy 3. Cohort 3: 75 participants who received upadacitinib 45 mg QD in Induction Phase and did not achieve clinical response and received upadacitinib 45 mg QD in Extended Treatment in Substudy 2 Part 2 or in Study M14-675 Part 2 and achieved clinical response at Week 16 were re-randomized 1:1 and received blinded upadacitinib 30 mg QD or upadacitinib 15 mg QD in Substudy 3. Cohort 4: 20 participants who received double-blinded treatment of upadacitinib 7.5 mg QD for 8 weeks during Substudy 1 and achieved clinical response at Week 8 continued to receive blinded treatment of upadacitinib 7.5 mg QD in Substudy 3.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1302
Note: Adolescent participants who are 16 or 17 years old will be eligible to participate if approved by the country or regulatory/health authority. If approval has not been granted, only participants ≥18 years old will be enrolled. Adolescents must weigh ≥ 40 kilograms and meet the definition of Tanner Stage 5 at Screening Visit.
- Diagnosis of ulcerative colitis for 90 days or greater prior to Baseline, confirmed by colonoscopy during the Screening Period, with exclusion of current infection, colonic dysplasia and/or malignancy. Appropriate documentation of biopsy results consistent with the diagnosis of UC, in the assessment of the Investigator, must be available.
- Active ulcerative colitis with an Adapted Mayo score of 5 to 9 points and endoscopic sub score of 2 to 3 (confirmed by central reader).
- Demonstrated an inadequate response to, loss of response to, or intolerance to at least one of the following treatments including: oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic therapies in the opinion of the investigator.
Note: Participants who have had inadequate response, loss of response to conventional therapy, but have not failed biologic therapy (Non-bio-IR) and have received a prior biologic for up to 1 year may be enrolled, however they must have discontinued the biologic for reasons other than inadequate response or intolerance (e.g., change of insurance, well controlled disease) and must meet criteria for inadequate response, loss of response or intolerance to aminosalicylates, corticosteroids, and/or immunosuppressants as defined above.
- If female, participant must meet the criteria for Contraception Recommendations
- Female participants of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit prior to study drug dosing.
- Participant with current diagnosis of Crohn's disease (CD) or diagnosis of indeterminate colitis (IC)
- Current diagnosis of fulminant colitis and/or toxic megacolon
- Participant with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy
- Received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to Baseline
- Participant on azathioprine or 6-mercaptopurine within 10 days of Baseline
- Received intravenous corticosteroids within 14 days prior to Screening or during the Screening Period.
- Participant with previous exposure to Janus Activated Kinase (JAK) inhibitor (e.g., tofacitinib, baricitinib, filgotinib, upadacitinib).
- Screening laboratory and other analyses show any abnormal results meeting the exclusion criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description SS3: M14-675 clinical responders Placebo Participants in Study M14-675 (NCT03653026) who achieved clinical response defined by Adapted Mayo Score at Week 8 or Week 16 in that study and did not meet any study discontinuation criteria were eligible to enroll into Substudy 3. Participants were re-randomized and treated with a blinded treatment assignment (15 mg upadacitinib film-coated tablets once daily by mouth \[QD\], or 30 mg upadacitinib film-coated tablets QD, or placebo for upadacitinib film-coated tablets QD) for up to 52 weeks. SS1: Placebo Placebo During the 8-week induction phase in Substudy 1, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. SS2: Placebo/Upadacitinib 45 mg Placebo During the Substudy 2 Part 1 induction period, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label extended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks. SS1: Upadacitinib 7.5 mg Upadacitinib During the 8-week induction phase in Substudy 1, participants received 7.5 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. SS1: Upadacitinib 15 mg Upadacitinib During the 8-week induction phase in Substudy 1, participants received 15 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. SS1: Upadacitinib 45 mg Upadacitinib During the 8-week induction phase in Substudy 1, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks. SS1: Upadacitinib 30 mg Upadacitinib During the 8-week induction phase in Substudy 1, participants received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Additional participants were enrolled during the Substudy 1 analysis period and received 30 mg upadacitinib film-coated tablets once daily by mouth (QD) for 4 weeks. SS2: Placebo/Upadacitinib 45 mg Upadacitinib During the Substudy 2 Part 1 induction period, participants received placebo for upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label extended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks. SS2: Upadacitinib 45 mg/Upadacitinib 45 mg Upadacitinib During the Substudy 2 Part 1 induction period, participants received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for 8 weeks. Participants who did not achieve clinical response at Week 8 of Part 1 were enrolled in an open-label expended treatment period and received 45 mg upadacitinib film-coated tablets once daily by mouth (QD) for an additional 8 weeks. SS3: M14-675 clinical responders Upadacitinib Participants in Study M14-675 (NCT03653026) who achieved clinical response defined by Adapted Mayo Score at Week 8 or Week 16 in that study and did not meet any study discontinuation criteria were eligible to enroll into Substudy 3. Participants were re-randomized and treated with a blinded treatment assignment (15 mg upadacitinib film-coated tablets once daily by mouth \[QD\], or 30 mg upadacitinib film-coated tablets QD, or placebo for upadacitinib film-coated tablets QD) for up to 52 weeks.
- Primary Outcome Measures
Name Time Method Substudy 1: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 At Week 8 The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.
For Substudy 1, clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1.Substudy 2: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 At Week 8 The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.
For Substudy 2, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In Substudy 2, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.Substudy 3: Percentage Of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 52 At Week 52 The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.
For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.
- Secondary Outcome Measures
Name Time Method Substudy 2: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8 Baseline (Week 0), Week 8 The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
Substudy 1: Percentage Of Participants Achieving Clinical Remission Per Full Mayo Score at Week 8 At Week 8 The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
Substudy 1: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8 At Week 8 The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).Substudy 1: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2 At Week 2 The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease.
Clinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.Substudy 2: Percentage Of Participants Who Report No Bowel Urgency at Week 8 At Week 8 Bowel urgency was assessed by participants in a subject diary completed once a day.
Substudy 1: Percentage Of Participants With Endoscopic Improvement at Week 8 At Week 8 Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Substudy 1: Percentage Of Participants Who Achieved Histologic Improvement at Week 8 At Week 8 The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Histologic improvement was defined as decrease from baseline in Geboes score.Substudy 2: Percentage Of Participants With Endoscopic Remission at Week 8 At Week 8 Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Substudy 2: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8 At Week 8 Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1.
The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).
The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.Substudy 1: Percentage Of Participants With Endoscopic Remission at Week 8 At Week 8 Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Substudy 2: Percentage Of Participants With Endoscopic Improvement at Week 8 At Week 8 Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Substudy 2: Percentage Of Participants With Mucosal Healing at Week 8 At Week 8 Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).
The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.Substudy 3: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 52 Baseline (Week 0), Week 52 The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement.
Substudy 1: Change in Full Mayo Score From Baseline to Week 8 Baseline (Week 0), Week 8 The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \[confirmed by a central reader\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement. Clinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \> 1.
Substudy 2: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8 Baseline (Week 0), Week 8 The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.
Substudy 3: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Wk 52 and Were Corticosteroid Free for ≥ 90 Days Immediately Preceding Wk 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment At Week 52 The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.
For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.Substudy 3: Percentage of Participants With Endoscopic Improvement at Wk 52 Among Those Who Achieved Endoscopic Improvement at the End of the Induction Treatment At Week 52 Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Substudy 2: Percentage Of Participants Achieving Clinical Response Per Adapted Mayo Score at Week 8 At Week 8 The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).Substudy 2: Percentage Of Participants Achieving Clinical Response Per Partial Mayo Score at Week 2 At Week 2 The Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
The overall Partial Mayo score ranges from 0 to 6 with higher scores representing more severe disease.
Clinical response per Partial Mayo Score is defined as a decrease from Baseline ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.Substudy 2: Percentage Of Participants Who Reported No Abdominal Pain at Week 8 At Week 8 Abdominal pain was assessed by participants in a subject diary completed once a day.
Substudy 3: Percentage Of Participants With Endoscopic Remission At Week 52 At Week 52 Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Substudy 3: Percentage Of Participants With Mucosal Healing at Week 52 At Week 52 Mucosal healing is defined as an endoscopic score of 0 and Geboes score \< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).
The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.Substudy 3: Percentage Of Participants Who Reported No Abdominal Pain at Week 52 At Week 52 Abdominal pain was assessed by participants in a subject diary completed once a day.
Substudy 2: Percentage Of Participants Who Achieved Histologic Improvement at Week 8 At Week 8 The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. Histologic improvement was defined as decrease from baseline in Geboes score.
Substudy 3: Percentage Of Participants With Endoscopic Improvement at Week 52 At Week 52 Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).
Substudy 3: Percentage of Participants With Clinical Remission Per Adapted Mayo Score at Week 52 Among Those Who Achieved Clinical Remission at the End of the Induction Treatment At Week 52 The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.
For Substudy 3, clinical remission is defined as SFS ≤ 1 and not greater than Baseline, RBS of 0, and endoscopic subscore ≤ 1. In addition, evidence of friability during endoscopy in participants with otherwise "mild" endoscopic activity conferred an endoscopic subscore of 2.Substudy 3: Percentage Of Participants Who Maintained Clinical Response Per Adapted Mayo Score at Wk 52 Among Those Who Achieved Clinical Response at the End of the Induction Treatment At Week 52 The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal).
2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed).
3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical response is defined as a decrease from baseline in the Adapted Mayo score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).Substudy 3: Percentage Of Participants Who Reported No Bowel Urgency at Week 52 At Week 52 Bowel urgency was assessed by participants in a subject diary completed once a day.
Substudy 3: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 52 Baseline (Week 0), Week 52 The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement.
Substudy 3: Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 52 At Week 52 Histologic-endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1.
The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).
The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.
Trial Locations
- Locations (496)
The Vancouver Clinic, INC. PS /ID# 162333
🇺🇸Vancouver, Washington, United States
East View Medical Research, LLC /ID# 171183
🇺🇸Mobile, Alabama, United States
CB Flock Research Corporation /ID# 165980
🇺🇸Mobile, Alabama, United States
Citrus Valley Gastroenterology /ID# 151914
🇺🇸Covina, California, United States
UC San Diego Health System /ID# 155185
🇺🇸La Jolla, California, United States
Newport Huntington Medical Group /ID# 217005
🇺🇸Huntington Beach, California, United States
United Medical Doctors /ID# 207464
🇺🇸Los Alamitos, California, United States
TLC Clinical Research Inc /ID# 216829
🇺🇸Los Angeles, California, United States
Gastrointestinal Biosciences Clinical Trials, LLC /ID# 157080
🇺🇸Los Angeles, California, United States
Facey Medical Foundation /ID# 203133
🇺🇸Mission Hills, California, United States
United Medical Doctors - Murrieta /ID# 151211
🇺🇸Murrieta, California, United States
InSite Digestive Health Care - Oxnard /ID# 163414
🇺🇸Oxnard, California, United States
Inland Empire Clinical Trials, LLC /ID# 216038
🇺🇸Rialto, California, United States
Gastro Florida /ID# 155245
🇺🇸Clearwater, Florida, United States
Universal Axon Clinical Research /ID# 213461
🇺🇸Doral, Florida, United States
Palmetto Research, LLC /ID# 151716
🇺🇸Hialeah, Florida, United States
Cfagi Llc /Id# 202017
🇺🇸Maitland, Florida, United States
Moonshine Research Center, Inc /ID# 152533
🇺🇸Doral, Florida, United States
Nature Coast Clinical Research - Inverness /ID# 154064
🇺🇸Inverness, Florida, United States
Encore Borland-Groover Clinical Research /Id# 170912
🇺🇸Jacksonville, Florida, United States
SIH Research Mumtaz, Inc /ID# 163319
🇺🇸Kissimmee, Florida, United States
Advanced Research Institute, Inc /ID# 163098
🇺🇸New Port Richey, Florida, United States
Gastroenterology Associates of Central Georgia, LLC /ID# 165782
🇺🇸Macon, Georgia, United States
Atlanta Gastroenterology Spec /ID# 150548
🇺🇸Suwanee, Georgia, United States
Next Innovative Clinical Research - Chicago /ID# 216060
🇺🇸Chicago, Illinois, United States
NorthShore University HealthSystem /ID# 150555
🇺🇸Evanston, Illinois, United States
The University of Chicago DCAM /ID# 150547
🇺🇸Chicago, Illinois, United States
Northwest Health Care Associates /ID# 151590
🇺🇸Hoffman Estates, Illinois, United States
Carle Foundation Hospital /ID# 151137
🇺🇸Urbana, Illinois, United States
MediSphere Medical Research Center /ID# 152064
🇺🇸Evansville, Indiana, United States
University of Iowa Hospitals and Clinics /ID# 157058
🇺🇸Iowa City, Iowa, United States
Tri-State Gastroenterology /ID# 169811
🇺🇸Crestview Hills, Kentucky, United States
Houma Digestive Health Special /ID# 151844
🇺🇸Houma, Louisiana, United States
University of Maryland Med Ctr /ID# 150449
🇺🇸Baltimore, Maryland, United States
Louisana Research Center, LLC /ID# 150446
🇺🇸Shreveport, Louisiana, United States
Gastro Center of Maryland /ID# 200022
🇺🇸Columbia, Maryland, United States
Massachusetts General Hospital /ID# 165676
🇺🇸Boston, Massachusetts, United States
Clin Res Inst of Michigan, LLC /ID# 153027
🇺🇸Chesterfield, Michigan, United States
Revival Research Institute, LLC /ID# 207280
🇺🇸Southfield, Michigan, United States
Center for Digestive Health /ID# 161984
🇺🇸Troy, Michigan, United States
Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 157484
🇺🇸Wyoming, Michigan, United States
Minnesota Gastroenterology PA /ID# 151678
🇺🇸Saint Paul, Minnesota, United States
University of Mississippi Medical Center /ID# 213139
🇺🇸Jackson, Mississippi, United States
Washington University-School of Medicine /ID# 150485
🇺🇸Saint Louis, Missouri, United States
Aurora Medical Center - Grafto /ID# 151717
🇺🇸Grafton, Wisconsin, United States
Dartmouth-Hitchcock Medical Center /ID# 150549
🇺🇸Lebanon, New Hampshire, United States
AGA Clinical Research Associates, LLC /ID# 153040
🇺🇸Egg Harbor Township, New Jersey, United States
Atlantic Digestive Health Inst /ID# 150447
🇺🇸Morristown, New Jersey, United States
Rutgers Robert Wood Johnson /ID# 155248
🇺🇸New Brunswick, New Jersey, United States
Duplicate_University of New Mexico Department of Internal Medicine /ID# 214396
🇺🇸Albuquerque, New Mexico, United States
NY Scientific /ID# 152707
🇺🇸Brooklyn, New York, United States
NYU Langone Long Island Clinical Research Association /ID# 155272
🇺🇸Great Neck, New York, United States
DiGiovanna Institute for Medical Education & Research /ID# 201533
🇺🇸North Massapequa, New York, United States
Premier Medical Group - GI Division /ID# 153357
🇺🇸Poughkeepsie, New York, United States
Columbia Univ Medical Center /ID# 163410
🇺🇸New York, New York, United States
Richmond University Medical Center /ID# 201859
🇺🇸Staten Island, New York, United States
Gastoenterology Group of Rochester /ID# 151079
🇺🇸Rochester, New York, United States
Digestive Health Partners, P.A /ID# 167237
🇺🇸Asheville, North Carolina, United States
Atrium Health Carolinas Medical Center /ID# 156971
🇺🇸Charlotte, North Carolina, United States
Charlotte Gastroenterology and Hepatology, PLLC /ID# 150545
🇺🇸Charlotte, North Carolina, United States
Atlantic Gastroenterology Clinical Research /ID# 151899
🇺🇸Greenville, North Carolina, United States
The Ohio State University /ID# 169416
🇺🇸Columbus, Ohio, United States
Optimed Research, Ltd. /ID# 169696
🇺🇸Columbus, Ohio, United States
Hometown Urgent Care and Resea /ID# 200065
🇺🇸Dayton, Ohio, United States
Dayton Gastroenterology, Inc. /ID# 167631
🇺🇸Englewood, Ohio, United States
Great Lakes Medical Research, LLC /ID# 201772
🇺🇸Mentor, Ohio, United States
Ohio Clinical Research Partner /ID# 154068
🇺🇸Mentor, Ohio, United States
Healthcare Research Consultant /ID# 163100
🇺🇸Tulsa, Oklahoma, United States
Options Health Research, LLC /ID# 150554
🇺🇸Tulsa, Oklahoma, United States
Guthrie Medical Group, PC /ID# 150481
🇺🇸Sayre, Pennsylvania, United States
Penn State Health Colonnade /ID# 150259
🇺🇸State College, Pennsylvania, United States
Gastroenterology Associates, P.A. of Greenville /ID# 150541
🇺🇸Greenville, South Carolina, United States
East Tennessee Research Institute /ID# 203610
🇺🇸Johnson City, Tennessee, United States
Gastro One /ID# 151144
🇺🇸Germantown, Tennessee, United States
Inquest Clinical Research /ID# 164635
🇺🇸Baytown, Texas, United States
Texas Digestive Disease Consultants /ID# 209947
🇺🇸Cedar Park, Texas, United States
TX Clinical Research Institute /ID# 151526
🇺🇸Arlington, Texas, United States
Baylor Scott & White Center for Inflammatory Bowel Diseases /ID# 200770
🇺🇸Dallas, Texas, United States
DHAT Research Institute /ID# 151218
🇺🇸Garland, Texas, United States
Caprock Gastro Research, LLC /ID# 214754
🇺🇸Lubbock, Texas, United States
Carl R. Meisner Medical Clinic /ID# 171061
🇺🇸Sugar Land, Texas, United States
Tyler Research Institute, LLC /ID# 169146
🇺🇸Tyler, Texas, United States
Gastro Health & Nutrition - Victoria /ID# 167761
🇺🇸Victoria, Texas, United States
HP Clinical Research /ID# 163939
🇺🇸Bountiful, Utah, United States
Advanced Research Institute /ID# 162624
🇺🇸Ogden, Utah, United States
Ctr for Gastrointestinal Healt /ID# 153360
🇺🇸Franklin, Virginia, United States
Velocity Clinical Research - Salt Lake City /ID# 163181
🇺🇸West Jordan, Utah, United States
Emeritas Research Group, LLC /ID# 150258
🇺🇸Leesburg, Virginia, United States
Washington Gastroenterology /ID# 163629
🇺🇸Bellevue, Washington, United States
Cardio Alem /ID# 211280
🇦🇷San Isidro, Buenos Aires, Argentina
Gedyt /ID# 210015
🇦🇷Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina
Mautalen Salud e Investigacion /ID# 171173
🇦🇷Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina
Sanatorio 9 de Julio /ID# 150189
🇦🇷San Miguel de Tucuman, Tucuman, Argentina
Hospital Britanico de Buenos Aires /ID# 209495
🇦🇷Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina
Hospital Privado Univesitario /ID# 164185
🇦🇷Cordoba, Argentina
Macquarie University Hospital /ID# 211951
🇦🇺Macquarie University, New South Wales, Australia
Mater Misericordiae Limited /ID# 212685
🇦🇺South Brisbane, Queensland, Australia
Griffith University /ID# 211952
🇦🇺Southport, Queensland, Australia
Monash Medical Centre /ID# 150206
🇦🇺Clayton, Victoria, Australia
St Vincent's Hospital Melbourne /ID# 152472
🇦🇺Fitzroy Melbourne, Victoria, Australia
Ordensklinikum Linz GmbH Barmherzige Schwestern /ID# 150305
🇦🇹Linz, Oberoesterreich, Austria
Klinik Landstrasse /ID# 162866
🇦🇹Vienna, Wien, Austria
Medizinische Universitaet Wien /ID# 150614
🇦🇹Vienna, Wien, Austria
AZ-Delta /ID# 150330
🇧🇪Roeselare, Belgium
Vitebsk Regional Advanced Clin /ID# 169612
🇧🇾Витебск, Belarus
Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 150306
🇦🇹Salzburg, Austria
AZ Maria Middelares /ID# 150331
🇧🇪Gent, Belgium
University Clinical Centre of the Republic of Srpska /ID# 150209
🇧🇦Banja Luka, Republika Srpska, Bosnia and Herzegovina
University Clinical Centre of the Republic of Srpska /ID# 150706
🇧🇦Banja Luka, Republika Srpska, Bosnia and Herzegovina
University Clinical Center Tuzla /ID# 150211
🇧🇦Tuzla, Tuzlanski, Bosnia and Herzegovina
University Clinical Hospital Mostar /ID# 150705
🇧🇦Mostar, Bosnia and Herzegovina
Clinical Center University of Sarajevo /ID# 150208
🇧🇦Sarajevo, Bosnia and Herzegovina
Instituto Goiano de Gastroenterologia e Endoscopia Digestiva /ID# 153742
🇧🇷Goiânia, Goias, Brazil
Hospital Nossa Senhora das Graças /ID# 152480
🇧🇷Curitiba, Parana, Brazil
Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP /ID# 152484
🇧🇷Ribeirão Preto, Sao Paulo, Brazil
Faculdade de Medicina do ABC /ID# 152481
🇧🇷Santo André, Sao Paulo, Brazil
University of Calgary /ID# 151821
🇨🇦Calgary, Alberta, Canada
Allen Whey Khye Lim Professional Corporation /ID# 211168
🇨🇦Edmonton, Alberta, Canada
Covenant Health /ID# 158930
🇨🇦Edmonton, Alberta, Canada
University of Alberta - Zeidler Ledcor Centre /ID# 151100
🇨🇦Edmonton, Alberta, Canada
Okanagan Clinical Trials /ID# 153178
🇨🇦Kelowna, British Columbia, Canada
Percuro Clinical Research, Ltd /ID# 150367
🇨🇦Victoria, British Columbia, Canada
Hamilton Health Sciences - McMaster University Medical Centre /ID# 150365
🇨🇦Hamilton, Ontario, Canada
Ottawa Hospital Research Institute /ID# 151820
🇨🇦Ottawa, Ontario, Canada
CISSS de Chaudière-Appalaches, Hôpital Hotel-Dieu de Lévis /ID# 150361
🇨🇦Levis, Quebec, Canada
Toronto Digestive Disease Asso /ID# 150363
🇨🇦Vaughan, Ontario, Canada
CISSS de la Monteregie /ID# 159215
🇨🇦Greenfield Park, Quebec, Canada
Recherche GCP Research /ID# 151822
🇨🇦Montreal, Quebec, Canada
Centre Hospitalier de l'Universite de Montreal - CRCHUM /ID# 167169
🇨🇦Montreal, Quebec, Canada
Montreal General Hospital - McGill University Health Centre /ID# 170012
🇨🇦Montréal, Quebec, Canada
CIUSSS de l'Estrie - CHUS /ID# 150366
🇨🇦Sherbrooke, Quebec, Canada
Research Group /ID# 203176
🇨🇱Santiago, Region Metropolitana De Santiago, Chile
M y F Estudios Clínicos /ID# 200107
🇨🇱Santiago, Region Metropolitana Santiago, Chile
CTR Estudios Clinicos /ID# 200110
🇨🇱Providencia, Chile
Hospital Guillermo Grant Benavente de Concepción /ID# 212424
🇨🇱Concepción, Chile
Centro de Investigaciones Clínicas Viña del Mar /ID# 150212
🇨🇱Viña del Mar, Valparaíso, Chile
Hospital Clinico Universidad De Los Andes /ID# 207422
🇨🇱Santiago, Chile
Affiliated Taihe Hospital of Hubei University of Medicine /ID# 216405
🇨🇳Shiyan, Hubei, China
The First Affiliated Hospital, Sun Yat-sen University /ID# 150455
🇨🇳Guangzhou, Guangdong, China
The Sixth Affiliated Hosp Sun /ID# 150456
🇨🇳Guangzhou, Guangdong, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 167088
🇨🇳Wuhan, Hubei, China
The First Affiliated Hospital of Nanchang University /ID# 211750
🇨🇳Nanchang, Jiangxi, China
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167078
🇨🇳Wuhan, Hubei, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 150461
🇨🇳Shanghai, Shanghai, China
Shanghai Tenth People's Hospital /ID# 150460
🇨🇳Shanghai, Shanghai, China
Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 165815
🇨🇳Shanghai, Shanghai, China
Xiangya Hospital Central South University /ID# 167229
🇨🇳Changsha, China
Sir Run Run Shaw Hospital,Meical School Zhejiang University /ID# 150454
🇨🇳Hangzhou, Zhejiang, China
Shengjing Hospital of China Medical University /ID# 166920
🇨🇳Shenyang, China
West China Hospital, Sichuan University /ID# 167040
🇨🇳Chengdu, China
Tianjin Medical University General Hospital /ID# 170604
🇨🇳Tianjin, China
Clinical Hospital Dubrava /ID# 150213
🇭🇷Zagreb, Grad Zagreb, Croatia
Corporacion Hospitalaria Juan Cuidad Sede Denominada Hospital Universitario Mayo /ID# 151564
🇨🇴Bogota DC, Cundinamarca, Colombia
Hospital Universitario de San /ID# 155387
🇨🇴Medellin, Colombia
Klinicki bolnicki centar Zagreb /ID# 150225
🇭🇷Zagreb, Grad Zagreb, Croatia
Klinicki bolnicki centar Zagreb /ID# 150709
🇭🇷Zagreb, Grad Zagreb, Croatia
Vilo Research Group Inc /ID# 212624
🇺🇸Houston, Texas, United States
The Polyclinic /ID# 164369
🇺🇸Seattle, Washington, United States
Duplicate_Klinicki bolnicki centar Osijek /ID# 150216
🇭🇷Osijek, Osjecko-baranjska Zupanija, Croatia
Klinicki bolnicki centar Rijeka /ID# 150708
🇭🇷Rijeka, Primorsko-goranska Zupanija, Croatia
Klinicki bolnicki centar Split /ID# 213988
🇭🇷Split, Splitsko-dalmatinska Zupanija, Croatia
Zadar General Hospital /ID# 150221
🇭🇷Zadar, Croatia
CTCenter MaVe s.r.o. /ID# 150904
🇨🇿Olomouc, Czechia
CliniCore International, LLC /ID# 152062
🇺🇸Houston, Texas, United States
Baylor College of Medicine - Baylor Medical Center /ID# 150486
🇺🇸Houston, Texas, United States
Hepato-Gastroenterologie HK, s.r.o. /ID# 150912
🇨🇿Hradec Kralove, Czechia
Centex Studies, Inc. - Houston /ID# 201216
🇺🇸Houston, Texas, United States
ARTROSCAN s.r.o. /ID# 150401
🇨🇿Ostrava, Czechia
Nemocnice Pardubickeho kraje, a.s. /ID# 213539
🇨🇿Pardubice, Czechia
Axon Clinical, s.r.o. /ID# 152479
🇨🇿Praha, Czechia
Nemocnice Milosrdnych sester sv. Karla Boromejskeho v Praze /ID# 216221
🇨🇿Praha, Czechia
Tartu University Hospital /ID# 150418
🇪🇪Tartu Linn, Tartumaa, Estonia
ISCARE a.s. /ID# 209278
🇨🇿Praha, Czechia
North Estonia Medical Centre /ID# 160870
🇪🇪Mustamäe Linnaosa, Harjumaa, Estonia
East Tallinn Central Hospital /ID# 150417
🇪🇪Kesklinna Linnaosa, Harjumaa, Estonia
Tampere University Hospital /ID# 150114
🇫🇮Tampere, Pirkanmaa, Finland
Duplicate_Helsinki Univ Central Hospital /ID# 150407
🇫🇮Helsinki, Finland
Turku University Hospital /ID# 168301
🇫🇮Turku, Finland
Keski-Suomen Sairaala Nova /ID# 155666
🇫🇮Jyvaskyla, Finland
Laakarikeskus Ikioma /ID# 150121
🇫🇮Mikkeli, Finland
HCL - Hôpital Lyon Sud /ID# 152539
🇫🇷Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France
CHU Hopital Nord /ID# 163508
🇫🇷Marseille, Bouches-du-Rhone, France
CHU Montpellier - Hôpital Saint Eloi /ID# 200006
🇫🇷Montpellier Cedex 5, Herault, France
GI Specialists of Houston /ID# 202327
🇺🇸Houston, Texas, United States
CHD Vendée- La Roche-sur-Yon - Les Oudairies /ID# 154452
🇫🇷La Roche Sur Yon, France
CHU Amiens-Picardie Site Sud /ID# 163456
🇫🇷Amiens CEDEX 1, Somme, France
CHU de Saint-Etienne, Hopital Nord /ID# 154453
🇫🇷SAINT-ETIENNE Cedex 1, France
Universitatsklinikum Mannheim /ID# 150173
🇩🇪Mannheim, Baden-Wuerttemberg, Germany
Virginia Mason Medical Center /ID# 153026
🇺🇸Seattle, Washington, United States
Universitaetsklinimum Tuebingen /ID# 150767
🇩🇪Tubingen, Baden-Wuerttemberg, Germany
Gastroenterologische Gemeinschaftspraxis Herne /ID# 214574
🇩🇪Herne, Nordrhein-Westfalen, Germany
MVZ fuer Gastroenterlogie am Bayerischen Platz /ID# 150766
🇩🇪Berlin, Germany
Agaplesion Markus Krankenhaus /ID# 161982
🇩🇪Frankfurt am Main, Germany
Praxis medicum /ID# 150166
🇩🇪Wiesbaden, Germany
General Hospital of Athens Laiko /ID# 208669
🇬🇷Athens, Attiki, Greece
Medizinisches Versorgungszentrum Portal 10 /ID# 207135
🇩🇪Muenster, Germany
General Hospital of Chest Diseases of Athens SOTIRIA /ID# 202100
🇬🇷Athens, Attiki, Greece
University General Hospital of Heraklion PA.G.N.I /ID# 150250
🇬🇷Heraklion, Kriti, Greece
Markusovszky Egyetemi Oktatokorhaz /ID# 150313
🇭🇺Szombathely, Vas, Hungary
Bekes Megyei Kozponti Korhaz /ID# 151572
🇭🇺Bekescsaba, Hungary
Mentahaz Maganorvosi Kozpont /ID# 205884
🇭🇺Szekesfehervar, Hungary
St James Hospital /ID# 150320
🇮🇪Dublin 8, Dublin, Ireland
St Vincent's University Hospital /ID# 150318
🇮🇪Elm Park, Dublin, Ireland
Mercy University Hospital /ID# 151529
🇮🇪Cork, Ireland
University Hospital Galway /ID# 150319
🇮🇪Galway, Ireland
Soroka University Medical Center /ID# 156561
🇮🇱Be'er Sheva, HaDarom, Israel
Rambam Health Care Campus /ID# 150325
🇮🇱Haifa, Israel
Shaare Zedek Medical Center /ID# 161677
🇮🇱Jerusalem, Israel
Hadassah Medical Center-Hebrew University /ID# 165118
🇮🇱Jerusalem, Israel
Istituto Clinico Humanitas /ID# 151361
🇮🇹Rozzano, Milano, Italy
Azienda Ospedaliera San Camillo Forlanini /ID# 151360
🇮🇹Rome, Lazio, Italy
Fondazione PTV Policlinico Tor Vergata /ID# 150338
🇮🇹Rome, Roma, Italy
IRCCS Ospedale Sacro Cuore Don Calabria /ID# 201725
🇮🇹Negrar, Verona, Italy
Aichi Medical University Hospital /ID# 151993
🇯🇵Nagakute-shi, Aichi, Japan
Nagoya University Hospital /ID# 152709
🇯🇵Nagoyashi, Aichi, Japan
Toyohashi Municipal Hospital /ID# 171457
🇯🇵Toyohashi-shi, Aichi, Japan
Ieda Hospital /ID# 157781
🇯🇵Toyota-shi, Aichi, Japan
Toho University Sakura Medical Center /ID# 151936
🇯🇵Sakura-shi, Chiba, Japan
Fukui Prefectural Hospital /ID# 210448
🇯🇵Fukui-shi, Fukui, Japan
Fukuoka University Chikushi Hospital /ID# 152628
🇯🇵Chikushino-shi, Fukuoka, Japan
Kyushu University Hospital /ID# 152526
🇯🇵Fukuoka-shi, Fukuoka, Japan
Ogaki Municipal Hospital /ID# 208225
🇯🇵Ogaki-shi, Gifu, Japan
Kurume University Hospital /ID# 151976
🇯🇵Kurume-shi, Fukuoka, Japan
Obihiro kosei Hospital /ID# 210412
🇯🇵Obihiro-shi, Hokkaido, Japan
Sapporo Tokushukai Hospital /ID# 209397
🇯🇵Sapporo-shi, Hokkaido, Japan
Hyogo College of Medicine College Hospital /Id# 152434
🇯🇵Nishinomiya-shi, Hyogo, Japan
Kanazawa University Hospital /ID# 205099
🇯🇵Kanazawa-shi, Ishikawa, Japan
Imamura General Hospital /ID# 227134
🇯🇵Kagoshima-shi, Kagoshima, Japan
Kyoto University Hospital /ID# 211758
🇯🇵Kyoto-shi, Kyoto, Japan
Showa University Fujigaoka Hospital /ID# 208222
🇯🇵Yokohama-shi, Kanagawa, Japan
Japanese Red Cross Kyoto Daiichi Hosital /ID# 152359
🇯🇵Kyoto-shi, Kyoto, Japan
Mie University Hospital /ID# 205362
🇯🇵Tsu-shi, Mie, Japan
Yokkaichi Hazu Medical Center /ID# 214347
🇯🇵Yokkaichi-shi, Mie, Japan
Saiseikai Niigata Hospital /ID# 209916
🇯🇵Niigata-shi, Niigata, Japan
Chikuba Hospital for Proctological and Gastrointestinal Diseases /ID# 157821
🇯🇵Kurashiki-shi, Okayama, Japan
Ishida Clinic of IBD and Gastroenterology /ID# 210117
🇯🇵Oita-shi, Oita, Japan
Niigata University Medical & Dental Hospital /ID# 218048
🇯🇵Niigata-shi, Niigata, Japan
Okayama University Hospital /ID# 217923
🇯🇵Okayama-shi, Okayama, Japan
Kitano Hospital /ID# 210395
🇯🇵Osaka-shi, Osaka, Japan
Osaka City University Hospital /ID# 152682
🇯🇵Osaka-shi, Osaka, Japan
Saga University Hospital /ID# 209268
🇯🇵Saga-shi, Saga, Japan
Shimane University Hospital /ID# 208899
🇯🇵Izumo-shi, Shimane, Japan
Tokitokai Tokito clinic /ID# 152677
🇯🇵Saitama-shi, Saitama, Japan
National Hospital Organization Higashi-Ohmi General Medical Center /ID# 210709
🇯🇵Higashi-ohmi-shi, Shiga, Japan
Tokai University Hachioji Hospital /ID# 152587
🇯🇵Hachioji-shi, Tokyo, Japan
NHO Shizuoka Medical Center /ID# 163572
🇯🇵Sunto-gun, Shizuoka, Japan
St.Luke's International Hospital /ID# 208074
🇯🇵Chuo-ku, Tokyo, Japan
Center Hospital of the National Center for Global Health and Medicine /ID# 209267
🇯🇵Shinjuku-ku, Tokyo, Japan
Tokyo Women's Medical University Hospital /ID# 205977
🇯🇵Shinjuku-ku, Tokyo, Japan
Yamanashi Prefectural Central Hospital /ID# 151908
🇯🇵Kofu-shi, Yamanashi, Japan
Tokuyama Central Hospital /ID# 216993
🇯🇵Shunan-shi, Yamaguchi, Japan
Shoyukai Fujita Gastroenterological Hospital /ID# 216492
🇯🇵Takatsuki-shi, Japan
The Catholic University of Korea, ST. Vincent's Hospital /ID# 150347
🇰🇷Suwon, Gyeonggido, Korea, Republic of
Hayang University GuriHospital /ID# 150344
🇰🇷Guri, Gyeonggido, Korea, Republic of
CHA University Bundang Medical Center /ID# 159479
🇰🇷Seongnam si, Gyeonggido, Korea, Republic of
Kangbuk Samsung Hospital /ID# 150348
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Yonsei University Health System Severance Hospital /ID# 159478
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Yeungnam University Medical Center /ID# 150345
🇰🇷Daegu, Korea, Republic of
Samsung Medical Center /ID# 150346
🇰🇷Seoul, Korea, Republic of
Dong-A University Hospital /ID# 159480
🇰🇷Busan, Korea, Republic of
Pusan National University Hospital /ID# 159481
🇰🇷Busan, Korea, Republic of
Pauls Stradins Clinical University Hospital /ID# 151409
🇱🇻Riga, Latvia
Asan Medical Center /ID# 150900
🇰🇷Seoul, Korea, Republic of
Riga East Clinical University Hospital /ID# 150354
🇱🇻Riga, Latvia
Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 150357
🇱🇹Kaunas, Lithuania
Klaipeda Seamens Hospital /ID# 154319
🇱🇹Klaipeda, Lithuania
Vilnius University Hospital /ID# 154318
🇱🇹Vilnius, Lithuania
Hospital Sultanah Bahiyah /ID# 151687
🇲🇾Alor Setar, Kedah, Malaysia
Universiti Kebangsaan Malaysia (UKM) Medical Centre /ID# 151689
🇲🇾Kuala Lumpur, Selangor, Malaysia
Hospital Ampang /ID# 151298
🇲🇾Ampang, Malaysia
Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 150710
🇲🇽Guadalajara, Jalisco, Mexico
Leids Universitair Medisch Centrum /ID# 152624
🇳🇱Leiden, Netherlands
Academisch Medisch Centrum /ID# 150647
🇳🇱Amsterdam, Netherlands
Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 150256
🇲🇽Monterrey, Nuevo Leon, Mexico
Radboud Universitair Medisch Centrum /ID# 151700
🇳🇱Nijmegen, Gelderland, Netherlands
Universitair Medisch Centrum Utrecht /ID# 152775
🇳🇱Utrecht, Netherlands
Akershus universitetssykehus /ID# 150317
🇳🇴Nordbyhagen, Akershus, Norway
Universitetssykehuset Nord-Norge /ID# 152835
🇳🇴Tromsø, Troms, Norway
Gastromed /Id# 216197
🇵🇱Torun, Kujawsko-pomorskie, Poland
Centrum Zdrowia MDM /ID# 150351
🇵🇱Warszawa, Mazowieckie, Poland
Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 150580
🇵🇱Warszawa, Mazowieckie, Poland
NZOZ Vivamed /ID# 216742
🇵🇱Warszawa, Mazowieckie, Poland
Endoskopia Sp. z o.o. /ID# 150765
🇵🇱Sopot, Pomorskie, Poland
Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 215732
🇵🇱Warszawa, Mazowieckie, Poland
Hospital da Senhora da Oliveira Guimaraes, EPE /ID# 151607
🇵🇹Guimaraes, Braga, Portugal
Unidade Local de Saúde do Alto Minho, EPE - Hospital Conde de Bertiandos /ID# 151609
🇵🇹Ponte de Lima, Viana Do Castelo, Portugal
Hospital Garcia de Orta, EPE /ID# 151613
🇵🇹Almada, Portugal
Centro Hospitalar Universitario Lisboa Central, EPE - Hospital dos Capuchos /ID# 151611
🇵🇹Lisboa, Portugal
NW State Medical Univ na Mechn /ID# 169322
🇷🇺St. Petersburg, Leningradskaya Oblast, Russian Federation
Perm Clinical Center of the Federal Medical and Biological Agency /ID# 150386
🇷🇺Perm, Permskiy Kray, Russian Federation
Kazan State Medical University /ID# 166042
🇷🇺Kazan, Tatarstan, Respublika, Russian Federation
LLC Novaya Klinika /ID# 208107
🇷🇺Pyatigorsk, Stavropol Skiy Kray, Russian Federation
Euromedservice /ID# 203800
🇷🇺Pushkin, Russian Federation
Duplicate_Stavropol State Medical Univ /ID# 150387
🇷🇺Stavropol, Russian Federation
Military Medical Academy /ID# 150429
🇷🇸Belgrade, Beograd, Serbia
Clinical Hosp Center Zvezdara /ID# 150427
🇷🇸Belgrade, Beograd, Serbia
University Clinical Center Serbia /ID# 150428
🇷🇸Belgrade, Beograd, Serbia
Clin Hosp Ctr Bezanijska Kosa /ID# 150426
🇷🇸Belgrade, Beograd, Serbia
University Clinical Center of Nis /ID# 151903
🇷🇸NIS, Nisavski Okrug, Serbia
University Clinical Center Kragujevac /ID# 150430
🇷🇸Kragujevac, Sumadijski Okrug, Serbia
Clinical Center Vojvodina /ID# 150764
🇷🇸Novi Sad, Vojvodina, Serbia
General Hospital Leskovac /ID# 217880
🇷🇸Leskovac, Serbia
Gleneagles Medical Centre /ID# 206018
🇸🇬Singapore, Singapore
Tan Tock Seng Hospital /ID# 150443
🇸🇬Singapore, Singapore
Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 150868
🇸🇰Banska Bystrica, Slovakia
Medak s.r.o. /ID# 150480
🇸🇰Bratislava, Slovakia
Slovak Research Center Team Me /ID# 150257
🇸🇰Ilava, Slovakia
Fakultna nemocnica s poliklinikou Nove Zamky /ID# 211370
🇸🇰Nove Zamky, Slovakia
GASTRO I., s.r.o. /ID# 150472
🇸🇰Presov, Slovakia
MD Search /ID# 167293
🇿🇦Boksburg North, Gauteng, South Africa
Clinresco Centers /ID# 163622
🇿🇦Johannesburg, Gauteng, South Africa
Wits Clinical Research , Wits Health Consortium (PTY) Ltd /ID# 150785
🇿🇦Johannesburg, Gauteng, South Africa
Lenasia Clinical Trial Centre /ID# 214344
🇿🇦Johannesburg, Gauteng, South Africa
Wits Clinical Research Site /ID# 150496
🇿🇦Johannesburg, Gauteng, South Africa
Spoke Research Inc /ID# 162202
🇿🇦CAPE TOWN Milnerton, Western Cape, South Africa
Private Practice Dr MN Rajabally /ID# 155144
🇿🇦Cape Town, Western Cape, South Africa
Hospital Unversitario Marques de Valdecilla /ID# 216620
🇪🇸Santander, Cantabria, Spain
Hospital Clínico Universitario de Santiago-CHUS /ID# 151065
🇪🇸Santiago de Compostela, A Coruna, Spain
Hospital Universitario Dr. Negrin /ID# 203937
🇪🇸Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Universitario A Coruna - CHUAC /ID# 203911
🇪🇸A Coruna, Spain
Hospital Universitario Reina Sofia /ID# 151066
🇪🇸Cordoba, Spain
Hospital Clinic de Barcelona /ID# 150612
🇪🇸Barcelona, Spain
Hospital Universitario La Paz /ID# 214539
🇪🇸Madrid, Spain
Hospital Universitario Ramon y Cajal /ID# 151067
🇪🇸Madrid, Spain
Hospital Universitario de Salamanca /ID# 150509
🇪🇸Salamanca, Spain
Sahlgrenska University Hospital /ID# 151496
🇸🇪Gothenburg, Vastra Gotalands Lan, Sweden
Hospital Universitario y Politecnico La Fe /ID# 150611
🇪🇸Valencia, Spain
Kantonsspital St. Gallen /ID# 152599
🇨🇭St. Gallen, Sankt Gallen, Switzerland
Universitätsspital Zürich /ID# 152591
🇨🇭Zürich, Zuerich, Switzerland
Inselspital, Universitätsspital Bern /ID# 152590
🇨🇭Bern, Switzerland
Erciyes University Medical Fac /ID# 150129
🇹🇷Melikgazi, Kayseri, Turkey
China Medical University Hospital /ID# 150571
🇨🇳Taichung City, Taiwan
National Cheng Kung University Hospital /ID# 151749
🇨🇳Tainan, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 150575
🇨🇳Kaohsiung, Taiwan
National Taiwan University Hospital /ID# 150574
🇨🇳Taipei City, Taiwan
Taipei Veterans General Hosp /ID# 151748
🇨🇳Taipei City, Taiwan
Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 150125
🇹🇷Istanbul, Turkey
Umraniye Training and Res Hosp /ID# 162659
🇹🇷Istanbul, Turkey
Marmara University Medical Fac /ID# 213969
🇹🇷Istanbul, Turkey
Mersin University Medical /ID# 157849
🇹🇷Mersin, Turkey
Gazi Universitesi Tip Fakultes /ID# 150127
🇹🇷Yenimahalle, Turkey
Municipal Enterprise "I.I. Mechnikov Dnipropetrovsk Regional Clinical Hospital" /ID# 207723
🇺🇦Dnipro, Ukraine
CNCE of Kharkiv Regional Council Regional Clinical Hospital /ID# 206940
🇺🇦Kharkiv, Ukraine
PE PMC Acinus, Medical and Diagnostic Center /ID# 217216
🇺🇦Kropyvnytskyi, Ukraine
Municipal Non-Commercial Enterprise Odesa Regional Clinical Hospital of the Od /ID# 151275
🇺🇦Odesa, Ukraine
Kyiv Municipal Clinical Hospital #18 /ID# 150372
🇺🇦Kyiv, Ukraine
Medical Center CONSILIUM MEDICAL /ID# 217446
🇺🇦Kyiv, Ukraine
CNPE of Kyiv Regional Council Kyiv Regional Hospital /ID# 217372
🇺🇦Kyiv, Ukraine
Lviv Regional Clinical Hospital /ID# 150375
🇺🇦Lviv, Ukraine
Hampshire Hospitals NHS Foundation Trust /ID# 150380
🇬🇧Basingstoke, Essex, United Kingdom
Royal Devon and Exeter NHS Trust Hospital /ID# 150379
🇬🇧Exeter, Devon, United Kingdom
NHS Greater Glasgow and Clyde /ID# 163787
🇬🇧Glasgow, Scotland, United Kingdom
Barts Health NHS Trust /ID# 150384
🇬🇧London, London, City Of, United Kingdom
Royal United Hospitals Bath /ID# 151532
🇬🇧Bath, United Kingdom
University Hospitals Birmingham NHS Foundation Trust /ID# 150382
🇬🇧Birmingham, United Kingdom
Calderdale and Huddersfield NHS Foundation Trust /ID# 217658
🇬🇧Huddersfield, United Kingdom
St George's University Hospitals NHS Foundation Trust /ID# 208374
🇬🇧Tooting, United Kingdom
University of Miami /ID# 215441
🇺🇸Miami, Florida, United States
Advanced Pharma /ID# 151719
🇺🇸Miami, Florida, United States
Indianapolis Gastroenterology /ID# 162901
🇺🇸Indianapolis, Indiana, United States
New Horizon Research Center /ID# 152474
🇺🇸Miami, Florida, United States
Crystal Pharmacology Research /ID# 151841
🇺🇸Miami, Florida, United States
Coral Research Clinic /ID# 150444
🇺🇸Miami, Florida, United States
San Diego Clinical Trials /ID# 212120
🇺🇸San Diego, California, United States
Medical Assoc Research Grp /ID# 169148
🇺🇸San Diego, California, United States
Las Vegas Medical Research /ID# 153044
🇺🇸Las Vegas, Nevada, United States
Consultants for Clinical Research /ID# 151679
🇺🇸Cincinnati, Ohio, United States
University of Cincinnati /ID# 164582
🇺🇸Cincinnati, Ohio, United States
The First Hospital of Jilin University /ID# 209986
🇨🇳Changchun, Jilin, China
The second Affiliated hospital of Zhejiang University school of Medicine /ID# 165807
🇨🇳Hangzhou, Zhejiang, China
Hospital de Clinicas de Porto Alegre /ID# 153743
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 215811
🇩🇪Saarbrücken, Saarland, Germany
South Denver Gastroenterology /ID# 151223
🇺🇸Lone Tree, Colorado, United States
Fiona Stanley Hospital /ID# 211640
🇦🇺Murdoch, Western Australia, Australia
Western States Clinical Res /ID# 158076
🇺🇸Wheat Ridge, Colorado, United States
Morales Vargas Centro de Investigacion S.C. /ID# 211325
🇲🇽Leon, Guanajuato, Mexico
Beaumont Hospital /ID# 150321
🇮🇪Beaumont, Dublin, Ireland
Delta Waves, Inc. /ID# 151721
🇺🇸Colorado Springs, Colorado, United States
Plains Clinical Research Center, LLC /ID# 170290
🇺🇸Fargo, North Dakota, United States
Universitätsspital Basel /ID# 161731
🇨🇭Basel, Basel-Stadt, Switzerland
Cotton-O'Neil Clinical Res Ctr /ID# 167182
🇺🇸Topeka, Kansas, United States
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 161981
🇩🇪Kiel, Schleswig-Holstein, Germany
ASST Rhodense/Presidio Ospedaliero di Rho /ID# 216610
🇮🇹Rho, Milano, Italy
Presidio Columbus-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Un /ID# 150333
🇮🇹Rome, Roma, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 150337
🇮🇹Bologna, Italy
ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico /ID# 150602
🇮🇹Milano, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 150334
🇮🇹Milan, Italy
A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 150253
🇮🇹Palermo, Italy
Birmingham Gastroenterology Associates P.C /ID# 151276
🇺🇸Birmingham, Alabama, United States
Univ of California San Francis /ID# 164581
🇺🇸San Francisco, California, United States
Hightower Clinical /ID# 216337
🇺🇸Oklahoma City, Oklahoma, United States
Digestive Disease Specialists /ID# 201056
🇺🇸Oklahoma City, Oklahoma, United States
Quality Medical Research /ID# 203426
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center /ID# 153355
🇺🇸Nashville, Tennessee, United States
Clinical Associates in Research Therapeutics of America, LLC /ID# 201260
🇺🇸San Antonio, Texas, United States
Southern Star Research Institute, LLC /ID# 169396
🇺🇸San Antonio, Texas, United States
Utah Gastroenternology - St. Mark's Office /ID# 163101
🇺🇸Salt Lake City, Utah, United States
Chu de Nice-Hopital L'Archet Ii /Id# 152606
🇫🇷Nice, Alpes-Maritimes, France
Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211885
🇺🇸Mesa, Arizona, United States
Western Connecticut Medical Group /ID# 169210
🇺🇸Danbury, Connecticut, United States
Universitair Ziekenhuis Leuven /ID# 150332
🇧🇪Leuven, Vlaams-Brabant, Belgium
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 150309
🇬🇷Athens, Greece
General Hospital of Thessaloniki Hippokrateio /ID# 209521
🇬🇷Thessaloniki, Greece
Tokatsu Tsujinaka Hospital /ID# 214962
🇯🇵Abiko-shi, Chiba, Japan
Tsujinaka Hospital Kashiwanoha /ID# 209130
🇯🇵Kashiwa-shi, Chiba, Japan
NHO Fukuyama Medical Center /ID# 206293
🇯🇵Fukuyama-shi, Hiroshima, Japan
Idzuro Imamura Hospital /ID# 206024
🇯🇵Kagoshima-shi, Kagoshima, Japan
Kinshukai Infusion Clinic /ID# 207864
🇯🇵Osaka-shi, Osaka, Japan
Japanese Red Cross Osaka Hospital /ID# 209476
🇯🇵Osaka-shi, Osaka, Japan
Hamamatsu University Hospital /ID# 205708
🇯🇵Hamamatsu-shi, Shizuoka, Japan
Delsol Research Management, Ll /Id# 170131
🇺🇸Chandler, Arizona, United States
University of Arizona /ID# 150553
🇺🇸Tucson, Arizona, United States
Southern Therapy and Advanced Research (STAR) LLC /ID# 170712
🇺🇸Jackson, Mississippi, United States
Arizona Arthritis & Rheumatology Research, PLLC /ID# 169822
🇺🇸Sun City, Arizona, United States
Theageneio Anticancer Hospital /ID# 163896
🇬🇷Thessaloniki, Greece
Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet /ID# 151523
🇭🇺Sopron, Hungary
West Tallinn Central Hospital /ID# 150419
🇪🇪Tallinn, Estonia
Meditres Kft. /ID# 151521
🇭🇺Kecskemet, Hungary
Instituto Medico de Alta Tecnologia Oncomédica S.A /ID# 207042
🇨🇴Monteria, Cordoba, Colombia
Poliklinika Solmed /ID# 211483
🇭🇷Zagreb, Grad Zagreb, Croatia
University General Hospital of Ioannina /ID# 164248
🇬🇷Ioannina, Greece
Nagoya City University Hospital /ID# 151950
🇯🇵Nagoya shi, Aichi, Japan
Juntendo University Urayasu Hospital /ID# 208781
🇯🇵Urayasu-shi, Chiba, Japan
Saiseikai Fukuoka Genaral Hospital /ID# 209479
🇯🇵Fukuoka-shi, Fukuoka, Japan
Hiroshima University Hospital /ID# 151951
🇯🇵Hiroshima-shi, Hiroshima, Japan
Semmelweis Egyetem /ID# 150312
🇭🇺Budapest, Hungary
Aoyama Clinic /ID# 152049
🇯🇵Kobe-shi, Hyogo, Japan
Sameshima Hospital /ID# 206672
🇯🇵Kagoshima-shi, Kagoshima, Japan
St. Marianna University School of Medicine Hospital /ID# 208654
🇯🇵Kawasaki-shi, Kanagawa, Japan
NHO Nagasaki Medical Center /ID# 209531
🇯🇵Omura-shi, Nagasaki, Japan
Saitama Medical Center /ID# 152031
🇯🇵Kawagoe-shi, Saitama, Japan
Erasmus Medisch Centrum /ID# 150308
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Kitasato University Kitasato Institute Hospital /ID# 152686
🇯🇵Minato-ku, Tokyo, Japan
Hirosaki National Hospital /ID# 152763
🇯🇵Hirosaki-shi, Aomori, Japan
Kitakyushu Municipal Med Ctr /ID# 152588
🇯🇵Kitakyushu, Fukuoka, Japan
Asahikawa Medical University Hospital /ID# 170289
🇯🇵Asahikawa-shi, Hokkaido, Japan
National Hospital Organization Mito Medical Center /ID# 152631
🇯🇵Higashi Ibaraki-gun, Ibaraki, Japan
Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 151506
🇯🇵Sapporo-shi, Hokkaido, Japan
Sapporo Higashi Tokushukai Hospital /ID# 208487
🇯🇵Sapporo-shi, Hokkaido, Japan
Yokohama City University Medical Center /ID# 169899
🇯🇵Yokohama shi, Kanagawa, Japan
Sapporo Medical University Hospital /ID# 206492
🇯🇵Sapporo-shi, Hokkaido, Japan
Kenseikai Dongo Hospital /ID# 208100
🇯🇵Yamatotakada-shi, Nara, Japan
Olla-Med Clinic /ID# 215332
🇷🇺Moscow, Russian Federation
Iwate Medical University Uchimaru Medical Center /ID# 203411
🇯🇵Morioka-shi, Iwate, Japan
Klaipeda University Hospital /ID# 158862
🇱🇹Klaipeda, Lithuania
Centro Hospitalar de Entre Douro e Vouga /ID# 152335
🇵🇹Santa Maria Da Feira, Porto, Portugal
School of Medicine University of Puerto Rico-Medical Science Campus /ID# 150358
🇵🇷San Juan, Puerto Rico
Immanuel Kant Baltic Federal University /ID# 200719
🇷🇺Kaliningrad, Kaliningradskaya Oblast, Russian Federation
National Hospital Organization Sendai Medical Center /ID# 209527
🇯🇵Sendai-shi, Miyagi, Japan
Osaka City General Hospital /ID# 152704
🇯🇵Osaka-shi, Osaka, Japan
Kingsbury Hospital /ID# 150497
🇿🇦Cape Town, Western Cape, South Africa
Toyonaka Municipal Hospital /ID# 217079
🇯🇵Toyonaka-shi, Osaka, Japan
Tokyo Medical And Dental University Hospital /ID# 152016
🇯🇵Bunkyo-ku, Tokyo, Japan
Centrum Medyczne Reuma Park /ID# 150349
🇵🇱Warszawa, Mazowieckie, Poland
Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 151606
🇵🇹Lisboa, Portugal
Republican hospital named after V.A. Baranov /ID# 206506
🇷🇺Petrozavodsk, Russian Federation
B+B MED, s.r.o. /ID# 150471
🇸🇰Kosice, Slovakia
Kyorin University Hospital /ID# 153194
🇯🇵Mitaka-shi, Tokyo, Japan
Yamagata University Hospital /ID# 171454
🇯🇵Yamagata-shi, Yamagata, Japan
Uni Malaya MC /ID# 150359
🇲🇾Kuala Lumpur, Malaysia
Centro Hospitalar Universitario de Sao Joao, EPE /ID# 151610
🇵🇹Porto, Portugal
National University Hospital /ID# 150453
🇸🇬Singapore, Singapore
Chung Shan Medical University Hospital /ID# 150573
🇨🇳Taichung, Taiwan
CCA Braga - Hospital de Braga /ID# 151608
🇵🇹Braga, Portugal
Medical Company Hepatolog /ID# 200197
🇷🇺Samara, Samarskaya Oblast, Russian Federation
Medical Center of the "Health /ID# 151274
🇺🇦Vinnytsya, Vinnytska Oblast, Ukraine
City Clinical Hospital #24 /ID# 150395
🇷🇺Moscow, Russian Federation
CNE Vinnytsya Regional Clinical Hospital named after N.I.Pirogov /ID# 216297
🇺🇦Vinnytsia, Ukraine
Medicor Research Inc /ID# 151101
🇨🇦Sudbury, Ontario, Canada
Clinical Research Trials of Florida, Inc. /ID# 201790
🇺🇸Tampa, Florida, United States
University of South Florida /ID# 214493
🇺🇸Tampa, Florida, United States
Mayo Clinic - Rochester /ID# 151677
🇺🇸Rochester, Minnesota, United States
AdventHealth Tampa /ID# 200272
🇺🇸Tampa, Florida, United States
Northwest Gastroenterology Clinic /ID# 152527
🇺🇸Portland, Oregon, United States
Wisconsin Center for Advanced Research, a division of GI Associates, LLC /ID# 151838
🇺🇸Milwaukee, Wisconsin, United States
Medical College of Wisconsin /ID# 151843
🇺🇸Milwaukee, Wisconsin, United States
Upeclin Fmb - Unesp /Id# 152485
🇧🇷Botucatu, Sao Paulo, Brazil
Kaiser Clinica e Hospital Dia /ID# 152483
🇧🇷Sao Jose Do Rio Preto, Sao Paulo, Brazil
Universitatsklinikum Munster /ID# 150158
🇩🇪Munster, Niedersachsen, Germany
Adobe Clinical Research LLC /ID# 155250
🇺🇸Tucson, Arizona, United States
Endoscopic Research, Inc. /ID# 151720
🇺🇸Orlando, Florida, United States
Omega Research Maitland, LLC /ID# 200269
🇺🇸Orlando, Florida, United States
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 151140
🇺🇸Ann Arbor, Michigan, United States
Huron Gastroenterology Assoc /ID# 152710
🇺🇸Ann Arbor, Michigan, United States
Clinical Trials of America /ID# 153448
🇺🇸Winston-Salem, North Carolina, United States
Wake Forest Baptist Medical Center /ID# 150448
🇺🇸Winston-Salem, North Carolina, United States
Pharmacorp Clinical Trials /ID# 153354
🇺🇸Charleston, South Carolina, United States
Nola Research Works, LLC /ID# 153356
🇺🇸New Orleans, Louisiana, United States
Montefiore Medical Center - Moses Campus /ID# 150543
🇺🇸Bronx, New York, United States
Advantage Clinical Trials /ID# 163938
🇺🇸Bronx, New York, United States
Infinite Clinical Trials /ID# 215340
🇺🇸Riverdale, Georgia, United States
Texas Digestive Disease Consultants /ID# 209804
🇺🇸Cedar Park, Texas, United States
Baylor Scott & White Center for Diagnostic Medicine /ID# 204499
🇺🇸Temple, Texas, United States
CHRU Lille - Hopital Claude Huriez /ID# 152607
🇫🇷Lille, Hauts-de-France, France
Teikyo University Hospital /ID# 208897
🇯🇵Itabashi-ku, Tokyo, Japan
Medical Research Center of CT /ID# 150482
🇺🇸Hamden, Connecticut, United States